Shanghai Henlius Biotech, Inc. (“Henlius”) announced this week that it has entered into a license and collaboration agreement with Eurofarma Laboratórios SA (“Eurofarma”), a Brazilian multinational biopharmaceutical company, for the development, manufacturing and commercialization of three biosimilar products in 16 Latin American countries. The three products are HANLIKANG® (rituximab), HANQUYOU® (trastuzumab), and HANBEITAI® (bevacizumab). Under the agreement terms, Henlius will receive up to a total of $50.5 million, including a $4.5 million upfront payment. Eurofarma will acquire exclusive rights to HANLIKANG® (rituximab) in 12 countries, as well as HANQUYOU® (trastuzumab) in 11 countries and HANBEITAI® (bevacizumab) in 15 countries. In addition, Eurofarma will obtain semi-exclusive rights to the three products in Brazil.
About Eurofarma
Eurofarma are the first 100% Brazillian-owned multinational pharmaceutical company. Since its establishment in 1972, Eurofarma has been operating in the health industry, producing and marketing products and services to improve people’s quality of life.
The post Henlius and Eurofarma Entered into a License Agreement for Henlius’ 3 Products in Latin America appeared first on Big Molecule Watch.